| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-626
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2008-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6cb16b1184780bf390bd4d7874ca53a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cade95bb3179dfd40246494a603b580
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_452918fd4a624e71a674996389c004b6 |
| publicationDate |
2010-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-101687034-A |
| titleOfInvention |
Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same |
| abstract |
It has been clarified that the cytotoxic activity of C3B3 diabody is induced at a lower concentration in a chemotherapy-resistant blood tumor cell line overexpressing MDR1 and HLA class IA proteins than in the parent strain. It has been also clarified that when this chemotherapy-resistant blood tumor cell line is pretreated with C3B3 diabody, the cytotoxic activity of the chemotherapeutic drug alone is enhanced and the drug is incorporated in an increased amount into the cells. Namely, it has been found out that C3B3 diabody exerts an antitumor activity on MDR1-expressing tumor cells overexpressing HLA class I and has an effect of overcoming the drug resistance. |
| priorityDate |
2007-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |